Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Total monthly reach
Estimated from 1 chart position in 1 market.
By chart position
- 🇺🇸US · Non-Profit#1095K to 30K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
2.5K to 15K🎙 Weekly cadence·16 episodes·Last published 2mo ago - Monthly Reach
Unique listeners across all episodes (30 days)
5K to 30K🇺🇸100% - Active Followers
Loyal subscribers who consistently listen
2K to 12K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Accrual Culture: Top Points for Site Selection - Timelines
Apr 2, 2026
20m 57s
Accrual Culture: Top Points for Site Selection - Responsiveness
Mar 6, 2026
17m 45s
GOG-3101 | TroFuse-20 Clinical Trial Update
Mar 5, 2026
13m 00s
The GOG Highlight Reel - January 2026
Feb 20, 2026
2h 15m 51s
KEYNOTE-B96 FDA APPROVAL REVIEW
Feb 16, 2026
19m 50s
Social Links & Contact
Official channels & resources
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 4/2/26 |  Accrual Culture: Top Points for Site Selection - Timelines | The GOG Foundation, Inc. would like to thank our commercial supporters for their support of the GOG GYN-LIVE Podcast:Corcept Therapeutics, GSK, Pfizer Oncology, Eli Lilly, Genmab, and Verastem ★ Support this podcast ★ | 20m 57s | ||||||
| 3/6/26 |  Accrual Culture: Top Points for Site Selection - Responsiveness | No description provided. | 17m 45s | ||||||
| 3/5/26 |  GOG-3101 | TroFuse-20 Clinical Trial Update | In this episode, we dive into GOG‑3101 TroFuse‑20—a Phase 3, randomized, active‑controlled, open‑label, multicenter study evaluating MK‑2870 monotherapy versus Treatment of Physician’s Choice as second‑ or third‑line therapy for patients with recurrent or metastatic cervical cancer. ★ Support this podcast ★ | 13m 00s | ||||||
| 2/20/26 |  The GOG Highlight Reel - January 2026 | The GOG Foundation, Inc. and GOG Partners are thrilled to present the “The GOG Highlight Reel”, an ongoing Education Series that showcases clinical trials and other newsworthy education, from major medical meetings throughout the year. The GOG Highlight Reel distills practice-changing information disclosed during recent major medical meetings into a two-and-a-half-hour segment. This comprehensive course examines recent clinical trial data in gynecologic malignancies, offering insights on data presentations, ongoing research, and drug approvals shaping the field. It addresses common gynecologic malignancies, aiding physicians in comprehending the evolving treatment landscape, including understanding trials in progress. Participants will receive a synthesis of recent studies and explore key components of clinical trials, gaining essential knowledge for research in these malignancies. Dynamic discussions will focus on emerging approved therapies and investigational agents, with an intent to provide insights into current (as well as future) advancements. Join us for a journey through clinical trials in ovarian, endometrial and cervical cancers, gaining the skills to navigate the latest oncology research and clinical care confidently.The GOG Foundation, Inc. is grateful for our commercial supporters for Independent Medical Education Support associated with this Symposium: GSK, Merck, AbbVie, AstraZeneca, Corcept Therapeutics, Verastem, Eisai, Natera, Karyopharm Therapeutics, BioNTechThe GOG Foundation, Inc. would also like to thank our sponsors for this symposium: Gilead, Faeth Therapeutics ★ Support this podcast ★ | 2h 15m 51s | ||||||
| 2/16/26 |  KEYNOTE-B96 FDA APPROVAL REVIEW | No description provided. | 19m 50s | ||||||
| 2/5/26 |  Accrual Culture: Top Points for Site Selection - Feasibility | No description provided. | 15m 10s | ||||||
| 1/30/26 |  Accrual Culture: Top Points for Site Selection - Enrollement | The GOG Partners Leadership presents the “Accrual Culture: An Education Series on How to Build a Successful Clinical Trial Network.” The purpose of this on-demand education series is to share key components for developing successful clinical trials. Our expert leaders will share their knowledge, experience, and best practices to integrate into your clinical trial process. ★ Support this podcast ★ | 18m 21s | ||||||
| 1/30/26 |  2026 Cervical Cancer Awareness Month Wrap Up | No description provided. | 11m 33s | ||||||
| 10/16/25 |  GOG Highlight Reel - January 2025 | The GOG Foundation, Inc. and GOG Partners are thrilled to present the “The GOG Highlight Reel”, an ongoing Education Series that showcases clinical trials and other newsworthy education, from major medical meetings throughout the year. A twice-yearly event, our most recent program took place Saturday, January 18, 2025, in Phoenix, Arizona alongside the 2025 NRG Oncology Winter Meeting.The GOG Highlight reel distills practice-changing information disclosed during recent major medical meetings into a two-and-a-half-hour segment. This comprehensive course takes a deep dive into clinical trials for gynecologic malignancies, offering insights on recent data presentations, ongoing research, and drug approvals shaping the field. It addresses common gynecologic malignancies, aiding physicians to comprehend the evolving treatment landscape, including understanding available trials in progress. Participants will receive a synthesis of recent studies and explore key components of clinical trials, gaining essential knowledge for research in these malignancies. Dynamic discussions analyze emerging approved therapies and investigational agents, providing insights into current (as well as future) advancements. Join us for a journey through clinical trials in ovarian, endometrial and cervical cancers, gaining the analytical skills to navigate the latest oncology research and clinical care confidently.The GOG Foundation, Inc. is grateful for our commercial supporters for Independent Medical Education Support associated with this Symposium: AbbVie, Acrivon Therapeutics, AstraZeneca, Corcept Therapeutics, GSK, and Eisai.The GOG Foundation, Inc., would also like to thank our sponsors for this symposium: Pfizer/Genmab and GSK. ★ Support this podcast ★ | 2h 33m 13s | ||||||
| 10/15/25 |  Research Algorithms, Clinical Trial Prioritization(s), Sequencing of Trials/Treatment | No description provided. | 15m 00s | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 10/15/25 |  The Ten Keys to Success When Building Your Clinical Trial Network | No description provided. | 41m 12s | ||||||
| 10/15/25 |  Budget and Contract Management; Strategic Insights on Maneuvering Through your Legal and Finance Discussions | No description provided. | 32m 34s | ||||||
| 10/15/25 |  Quality Management Processes - Large Sites | No description provided. | 35m 07s | ||||||
| 10/15/25 |  Enrollment and Accrual | No description provided. | 18m 44s | ||||||
| 10/15/25 |  The GOG Highlight Reel - July 2025 | The GOG Foundation, Inc. and GOG Partners are thrilled to present the “The GOG Highlight Reel”, an ongoing Education Series that showcases clinical trials and other newsworthy education, from major medical meetings throughout the year. This twice-yearly event was most recently held on Saturday, July 26, 2025, in Washington D.C. alongside the 2025 NRG Oncology Summer Meeting.The GOG Highlight Reel distills practice-changing information disclosed during recent major medical meetings into a two-and-a-half-hour segment. This comprehensive course takes a deep dive into clinical trials for gynecologic malignancies, offering insights on recent data presentations, ongoing research, and drug approvals shaping the field. It addresses common gynecologic malignancies, aiding physicians to comprehend the evolving treatment landscape, including understanding available trials in progress. Participants will receive a synthesis of recent studies and explore key components of clinical trials, gaining essential knowledge for research in these malignancies. Dynamic discussions analyze emerging approved therapies and investigational agents, providing insights into current (as well as future) advancements. Join us for a journey through clinical trials in ovarian, endometrial and cervical cancers, gaining the analytical skills to navigate the latest oncology research and clinical care confidently.The GOG Foundation, Inc. is grateful for our commercial supporters for Independent Medical Education Support associated with this Symposium: AbbVie, Acrivon, AstraZeneca, Corcept Therapeutics, Genelux, Gilead, GSK and KaryopharmThe GOG Foundation, Inc. would also like to thank our sponsors for this symposium: Pfizer Oncology | Genmab, GSK, and Verastem ★ Support this podcast ★ | 2h 28m 59s | ||||||
| 10/9/25 |  Accrual Culture: The Four Components of A Successful Clinical Trial Network | The GOG Partners Leadership presents the “Accrual Culture: An Education Series on How to Build a Successful Clinical Trial Network.” The purpose of this on-demand education series is to share key components for developing successful clinical trials. Our expert leaders will share their knowledge, experience, and best practices to integrate into your clinical trial process. ★ Support this podcast ★ | 11m 17s | ||||||
Showing 16 of 16
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
1 placement across 1 market.
Chart Positions
1 placement across 1 market.